Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

leuprolide acetate sustained-release microspheres PT105

A sustained-release (SR) injectable microsphere formulation composed of the acetate salt of leuprolide, a synthetic, long-acting nonapeptide analog of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, leuprolide binds to and activates the gonadotropin-releasing hormone receptor (GnRHR). The continuous stimulation of GnRHR by leuprolide results in both the desensitization of pituitary GnRHR and the inhibition of pituitary secretion of the gonadotropins follicle stimulating hormone (FSH) and luteinizing hormone (LH). In females, prolonged administration results in a decrease in estradiol production and suppression of ovarian function. Leuprolide also reduces testosterone production to castration levels and may inhibit androgen receptor-positive tumor progression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:leuprorelin acetate sustained-release microspheres PT105
Code name:PT 105
PT-105
PT105
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search